前列消癥汤治疗前列腺癌的网络靶标预测

中国医药导刊 ›› 2022, Vol. 24 ›› Issue (8): 782-792.

前列消癥汤治疗前列腺癌的网络靶标预测

刘明1，高亚1，张玉琴2，张俊华3，田金徽1，4*

1.兰州大学基础医学院循证医学中心，甘肃兰州 730000； 2.甘肃省中医院皮肤疮疡科，甘肃兰州 730000； 3.天津中医药大学循证医学中心，天津 300193； 4.甘肃省循证医学与临床转化重点实验室，甘肃兰州 730000

收稿日期:2022-05-18 修回日期:2022-11-02 出版日期:2022-08-28 发布日期:2022-08-28
基金资助:
兰州大学“中央高校基本科研业务费定向探索项目”（项目编号：lzujbky-2021-it18，项目名称：基于网络药理学和实验研究分析前列消癥汤治疗前列腺癌的作用机制）；甘肃省自然科学基金资助项目（项目编号：20JR10RA350，项目名称：基于VDR调控NF-kB信号通路探讨麻苓消疕颗粒治疗寻常型银屑病的作用机制）

Target Prediction of Qianlie Xiaozheng Decoction in the Treatment of Prostate Cancer Based on Network Pharmacology

1.Evidence-Based Medicine Center， School of Basic Medical Sciences， Lanzhou University，Gansu Lanzhou 730000， China; 2.Department of Dermatology， Gansu Provincial Hospital of Traditional Chinese Medicine， Gansu Lanzhou 730000， China; 3.Evidence-based Medicine Center of Tianjin University of Traditional Chinese Medicine， Tianjin 300193， China; 4.Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province， Gansu Lanzhou 730000， China

Received:2022-05-18 Revised:2022-11-02 Online:2022-08-28 Published:2022-08-28

摘要/Abstract

摘要： 目的：利用网络药理学预测前列消癥汤治疗前列腺癌（prostate cancer，PCa）的潜在作用靶标。方法：从中药系统药理学数据库与分析平台、传统中药综合数据库等数据库中获取前列消癥汤的有效成分。从GEO数据库中获取PCa基因芯片，分析癌组织与癌旁正常组织的差异表达基因。利用R软件预测出前列消癥汤治疗PCa潜在作用靶点，并在STRING数据库中预测潜在作用靶点的生物学过程。结果：从数据库中获取前列消癥汤有效化学成分68个，对应895个作用靶点。GSE69223基因芯片包含原发性PCa组织15个，癌旁正常组织15个。共1042个差异表达基因，其中645个基因表达升高，397个基因表达下降。来自多个中药的有效成分“quercetin”作用的靶基因最多，多个有效成分均作用于靶基因PGR。靶点参与的生物学过程有血液循环调节（blood circulation）、血管收缩调节（regulation of vasoconstriction）、类固醇的结合（steroid binding）、类固醇激素受体的激活（steroid hormone receptor activity）、细胞外区域（extracellular region）和质膜区域（plasma membrane region）等。靶点参与的KEGG信号通路有甾类激素的合成（steroid hormone biosynthesis）、癌症通路（pathways in cancer）和糖酵解/糖质新生（glycolysis/gluconeogenesis）等。结论：前列消癥汤通过多成分、多靶点和参与多生物学过程来治疗PCa，可通过改变PCa细胞的血液供应、细胞代谢、相关激素分泌和受体激活等干预癌细胞的增殖。

关键词: font-size:medium, ">前列消癥汤；前列腺癌；网络药理学；靶标预测

Abstract: Objective：To predict the potential targets of Qianlie Xiaozheng decoction in the trentment of prostate cancer (PCa) by the network pharmacology. Methods： The active ingredients of Qianlie Xiaozheng decoction were obtained from online databases， such as Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP， https：//tcmspw.com/tcmsp.php)， Traditional Chinese Medicines Integrated Database (TCMID， http：//www.megabionet.org/tcmid/). The PCa gene chip from the GEO database was used to analyze the differentially expressed of gene between cancer tissue and adjacent normal tissue. The R software was used to predict the potential targets of Qianlie Xiaozheng decoction in the treatment of PCa. The STRING database was used to predict the biological processes of potential targets. Results：A total of 68 effective chemical components of Qianlie Xiaozheng decoction were screened out from the databases， corresponding to 895 targets. The GSE69223 gene chip contains 15 primary PCa tissues and 15 adjacent normal tissues. A total of 1042 differentially expressed genes were identified， of which 645 genes were up-regulated and 397 were down-regulated. The active ingredient “quercetin” from several different herbals has the most targets. Multiple active ingredients act on the target gene PGR.The biological processes of potential targets inclnde in blood circulation， regulation of vasoconstriction， steroid binding， steroid hormone receptor activity， extracellular region and plasma membrane region, etc. The KEGG of potential targets involved insteroid hormone biosynthesis， pathways in cancer， and glycolysis/gluconeogenesis， etc. Conclusion： Qianlie Xiaozheng decoction through multi-component， multi-target and multi-biological process to treatment PCa, which can interfere with the proliferation of cancer cells by changing the blood supply， cell metabolism， related hormone secretion and receptor activation of cancer cells.

Key words: Qianlie Xiaozheng decoction, Prostate cancer, Network pharmacology, Target prediction

中图分类号:

刘明, 高亚, 张玉琴, 张俊华, 田金徽, . 前列消癥汤治疗前列腺癌的网络靶标预测[J]. 中国医药导刊, 2022, 24(8): 782-792.

LIU Ming, GAO Ya, ZHANG Yuqin, ZHANG Junhua, TIAN Jinhui, . Target Prediction of Qianlie Xiaozheng Decoction in the Treatment of Prostate Cancer Based on Network Pharmacology[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2022, 24(8): 782-792.

参考文献

[1]Siegel RL， Miller KD， Jemal A. Cancer statistics， 2020[J]. CA-A Cancer Journal for Clinicians， 2020， 70(1)：7-30.
     [2]Krahn MD， Bremner KE， Zagorski B， et al. Health care costs for state transition models in prostate cancer[J]. Medical Decision Making， 2014， 34(3)：366-378.
     [3]Krahn MD， Bremner KE， Luo J， et al. Health care costs for prostate cancer patients receiving androgen deprivation therapy： treatment and adverse events[J]. Current Oncology， 2014， 21(3)： e457-e465.
     [4]董石，姜苗，王佩佩，等. 中医药治疗前列腺癌研究进展[J]. 天津中医药， 2018， 35(10)：798-800.
     [5]张亚强，林飞，刘猷枋. 前列消癥汤治疗前列腺癌的临床观察[J]. 中国中西医结合外科杂志， 2006， 12(2)：83-85.
     [6]庞然，卢建新，高筱松，等. 前列消癥汤对晚期前列腺癌患者生活质量的作用[J]. 中国中西医结合外科杂志， 2010， 16(5)：572-574.
     [7]庞然，卢建新，高筱松，等. 前列消癥汤治疗激素难治性前列腺癌的临床研究[J]. 中国中西医结合外科杂志， 2013， 19(4)：374-377.
     [8]Meller S， Meyer HA， Bethan B， et al. Integration of tissue metabolomics， transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer[J]. Oncotarget， 2016， 7(2)：1421-1438.
     [9]陈红，王凯. 前列消癥汤辅助治疗前列腺癌的临床疗效[J]. 癌症进展， 2020， 18(14)：1489-1491.
     [10]廖春贤. 前列消癥汤治疗激素前列腺癌的临床疗效观察[J]. 齐齐哈尔医学院学报， 2016， 37(2)：170-172.
     [11]李聪，胡强，张燕翔，等. 槲皮素的药理学活性研究进展[J]. 湖北中医杂志， 2018， 40(6)：63-66.
     [12]李瑜，李永强，梁卫民，等. 槲皮素在顺铂诱导前列腺癌细胞凋亡中的增强作用[J]. 中华泌尿外科杂志， 2014， 35(5)：373-377.
     [13]邢红宇，朱明月，李伟，等. 槲皮素调控GSTP1甲基化抑制前列腺癌LNCap细胞增殖的机制研究[J]. 安徽医科大学学报， 2020， 55(12)：1921-1925.
     [14]宋静，白吉祥，王书惠，等. 槲皮素对人前列腺癌PC-3细胞自噬及磷脂酰肌醇3激酶/蛋白激B/哺乳动物雷帕霉素靶蛋白信号通路的影响[J]. 中国医学科学院学报， 2020， 42(5)：578-584.
     [15]康岳华. 孕酮受体基因（PGR）介导小鼠排卵的关键信号分子研究[D]. 重庆大学， 2014.
     [16]Arnett-Mansfield RL， deFazio A， Wain GV， et al. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium[J]. Cancer Research， 2001， 61(11)：4576-4582.
     [17]Skjefstad K， Richardsen E， Donnem T， et al. The prognostic role of progesterone receptor expression in non-small cell lung cancer patients： Gender-related impacts and correlation with disease-specific survival[J]. Steroids， 2015， 98：29-36.
     [18]Germán-Castelán L， Manjarrez-Marmolejo J， González-Arenas A， et al. Intracellular progesterone receptor mediates the increase in glioblastoma growth induced by progesterone in the rat brain[J]. Archives of Medical Research， 2016， 47(6)：419-426.
     [19]Yu Y， Liu L， Xie N， et al. Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control[J]. Journal of Clinical Endocrinology & Metabolism， 2013， 98(7)：2887-2896.
     [20]Grindstad T， Richardsen E， Andersen S， et al. Progesterone receptors in prostate cancer： Progesterone receptor B is the isoform associated with disease progression[J]. Scientific Reports， 2018， 27(1)：11358.
     [21]陈平圣，冯振卿，刘慧. 病理学[M]. 南京：东南大学出版社， 2017：333.
     [22]Lin CJ， Yun EJ， Lo UG， et al. The paracrine induction of prostate cancer progression by caveolin-1[J]. Cell Death & Disease， 2019， 10(11)：834.
     [23]Campos A， Burgos-Ravanal R， González MF， et al. Cell intrinsic and extrinsic mechanisms of caveolin-1-enhanced metastasis[J]. Biomolecules， 2019， 9(8)：314.
     [24]Wang N， Yao M， Xu J， et al. Autocrine activation of CHRM3 promotes prostate cancer growth and castration resistance via CaM/CaMKK-Mediated phosphorylation of akt[J]. Clinical Cancer Research， 2015， 21(20)：4676-4685.
     [25]Chen WY， Zeng T， Wen YC， et al. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer[J]. Cancer Letter， 2019， 440441(2019)：35-46.
     [26]Kaminski L， Torrino S， Dufies M， et al. PGC1α inhibits polyamine synthesis to suppress prostate cancer aggressiveness[J]. Cancer Research， 2019， 79(13)：3268-3280.
     [27]Agarwal N， Alex AB， Farnham JM， et al. Inherited variants in SULT1E1 and response to abiraterone acetate by men with metastatic castration refractory prostate cancer[J]. Journal of Urology， 2016， 196(4)：1112-1116.
     [28]Gu CY， Li GX， Zhu Y， et al. A single nucleotide polymorphism in CYP1B1 leads to differential prostate cancer risk and telomere length[J]. Journal of Cancer， 2018， 9(2)：269-274.
     [29]Mao Z， Ji A， Yang K， et al. Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer[J]. Medicine (Baltimore)， 2018， 97(42)： e12806.
     [30]Sanderson JT. The steroid hormone biosynthesis pathway as a target for endocrine-disrupting chemicals[J]. Toxicological Sciences， 2006， 94(1)：3-21.
     [31]Jing X， Yang F， Shao C， et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment[J]. Molecular Cancer， 2019， 18(1)：157.
     [32]Quintanal-Villalonga á， Chan JM， Yu HA， et al. Lineage plasticity in cancer： a shared pathway of therapeutic resistance[J]. Nature Reviewers Clinical Oncology， 2020， 17(6)：360-371.

快速检索引用检索图表检索高级检索